A neo-adjuvant chemotherapy study in patients with germline BRCA1/BRCA2 mutations and borderline resectable pancreatic cancer showed a complete pathologic response rate of 44.4% [43]. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.